Skip to main content

A case of ascetic fluid Mycobacterium aubagnense infection in a patient with severe peritoneal effusion

Abstract

Background

Mycobacterium aubagnense, which was first characterized in 2006, is a non-tuberculosis mycobacterium (NTM) that has only been isolated from respiratory secretions and joint fluid. With only four cases globally, the microbe has rarely been reported in human clinical cases and the strain has not been isolated from ascites.

Case presentation

To the best of our knowledge, this is the first time that M. aubagnense has been isolated from ascites samples of a patient with severe peritoneal effusion and normal liver functions. Anti-NTM therapy with moxifloxacin, ethambutol, and isoniazid combined with furosemide and spironolactone diuretic therapy relieved the symptoms after six months.

Conclusions

Increased puncture and drainage of ascites combined with diuretic treatment did not significantly relieve the ascites, leading to relapse with aggravated symptoms. The subsequent anti-NTM treatment with moxifloxacin, ethambutol, and isoniazid alleviated the degree of ascites. Therefore, we postulated that M. aubagnense infection was the potential cause of the difficult reduction of ascites in this patient. However, the ascites repeatedly occurred in the patient, which was attributed to M. aubagnense resistance due to insufficient medication time and repeated medication. The patient's underlying diseases may also result in ascites. Therefore, there is a need for careful analysis of the clinical significance of M. aubagnense.

Peer Review reports

Background

Mycobacterium aubagnense, a non-tuberculosis mycobacterium that is isolated from respiratory secretions and joint fluid, was first reported in 2006 [1]. It is commonly referred to as Aubagne, after the city where the first patient was identified. It is closely related to Mycobacterium mucogenicum, with a difference of 11 bases (99.2% similarity). Gene sequences of the two strains are also closely related to those of Mycobacterium phocaicum, with differences of less than 5 to 15 bases; hence, they are classified into the Mycobacterium mucogenicum group [[[2]]].

Case presentation

The 61 year old patient is a retired worker who has long lived in the city far away from natural environments such as rivers and wetlands. The patient had no smoking or drinking habits and had not undergone surgery. Due to abdominal fullness and recurrent lower limb edema, he was treated several times in the local hospital in 2019–2021. In April 2021, he was hospitalized at a local hospital. Abdominal computed tomography revealed ascites, and he was diagnosed with “viral Hepatitis B, cirrhosis, and ascites”. After the administration of diuretics to discharge ascites through puncture, there was no significant improvement in the patient’s condition. In May 2021, the symptoms aggravated, leading to his transfer to our hospital in July 2021. Physical examination revealed abdominal distention, positive fluid wave tremors, positive migratory dullness, no tenderness, rebound pain in the whole abdomen, and moderate pitting edema in both lower limbs. A blood sample was taken for analysis. The albumin level was 41.3 g/L, with normal liver functions. Renal function analysis revealed that urea, creatinine, and uric acid levels were 17.80 mmol/L, 149 μmol/L, and 64 μmol/L, respectively. The Hepatitis B virus-DNA test and the human immunodeficiency virus (HIV) test were negative. B-type ultrasonic inspection of ascites showed ascites (maximum anterior–posterior diameter of 7.5 cm), while epigastric CT scan revealed cirrhosis with ascites. Electronic gastroscopy further revealed portal hypertensive gastropathy. The extracted ascites were pale yellow and cloudy in texture, with 3.05 × 108/L white blood cell counts and 27.1 g/L albumin levels. The mucin of ascites serous membrane was characterized as weak positive. His liver functions were normal, portal vein pressure was slightly high, and the ascites were turbid with a high white blood cell count. The ascites were considered to have been caused by spontaneous peritonitis. However, cultures of the subsequent ascites were negative for bacteria and fungi, specific T-cell immune responses to Mycobacterium tuberculosis were positive, and the patient had no rebound tenderness. The patient was also considered to have tuberculous peritonitis; however, X-ray analysis did not show any signs of tuberculosis, with ascites adenosine deaminase levels determined to be 4.1 U/L. Eventually, the ascites were considered to have been caused by water fluid retention due to renal failure. Therefore, the patient was subjected to three times ascites drainage (draining 8000 mL of fluid), after which he was administered with furosemide and spironolone for diuretic drainage and discharged from the hospital. He was also prescribed diuretics, which he continued taking after discharge.

In October 2021, the patient was hospitalized again due to ascites and abdominal distention. B ultrasonography of ascites revealed ascites with a maximum anterior diameter of 9 cm. Blood sample analysis revealed normal liver functions. However, white blood cell counts in ascites were 4.09 × 108/L, and ascites mucin was positive. In addition, the Mycobacterium tuberculosis-specific t-cell immune responses were positive, the erythrocyte sedimentation rate was 20 mm/h, ascites adenosine deaminase levels were 5U/L, and the ascites cultures were negative for bacteria and fungi. Chest CT scan was negative for tuberculosis infection. The patient was advised to undergo tuberculous/non-tuberculosis mycobacteria identification, which he rejected. Therefore, tuberculous peritonitis was temporarily considered, and anti-tuberculosis medications, including moxifloxacin, ethambutol, and isoniazid administered. During hospitalization, the ascites were repeatedly extracted. After discharge, the anti-tuberculous drugs were continued for 6 months, and furosemide and spironolacone diuresis were given for more ascites. However, the patient often stopped taking the drugs due to nausea and vomiting.

In May 2022, the patient was hospitalized for the third time. He had a flat abdomen, and an upper abdominal CT scan revealed that the degree of ascites was significantly reduced. The anti-nuclear antibody and tuberculosis antibody tests were negative, but Mycobacterium tuberculosis-specific T-cell immune responses were positive. A negative test result for antinuclear antibodies ruled out autoimmune diseases. The accuracy of the tuberculosis antibody detection assay, which is often used to assist in diagnosis, was insufficient. A negative result does not rule out Mycobacterium tuberculosis (MTB) infections. The positive MTB-specific T-cell immune responses indicate past or recent MTB infections. The ascites samples were extracted and sent to Zhejiang Shengting Biotechnology Limited Company to identify MTB and the 168 NTM species using the high-throughput nanopore system. Full length sequencing was performed to identify the 16 anti-MTB drug resistance genes, including isoniazid, quinolones and ethambutol, and 5 anti-NTM drug resistance genes, including clarithromycin and Amica magnitude. The M. aubagnense was detected, but no drug-resistance genes were detected. Therefore, given the difficulty associated with the elimination of Mycobacterium obaneum-associated ascites, administrations of moxifloxacin, ethambutol, and isoniazid anti-NTM treatments were continued. After discharge, although the patient stopped taking the medicines several times, ascites in the follow-up visits were much less than in 2021 and the patient was prone to relapses (Fig. 1).

Fig. 1
figure 1

a A CT scan micrograph showing massive ascites on admission; b A CT scan micrograph showing persistent ascites; c A CT scan micrograph showing reduced ascites after anti-NTM treatment; d Ascites from the first peritoneal punch; e Gastric fundus with no obvious varicose veins under digestive endoscopy; f The esophagus with no obvious varicose veins under digestive endoscopy

Discussion and conclusions

Currently, only two cases of M. aubagnense infections have been reported in China and another two in France [3,4,5]. None of the patients in China had any clinical disease manifestations [3,4]. The first case in France was a 55-year-old man admitted to a hospital with hemoptysis, where the CT scan revealed tuberculosis infection. However, M. aubagnense was isolated from his bronchial aspirate. Clarithromycin and amikacin have good clinical effects against M. aubagnense infections. The second case was a 91-year-old female who had undergone a revision hip prosthesis surgery for suspected septicemia. She had a fever (39 °C), and the X-ray revealed osteolysis with necrosis and pathological fractures. M. aubagnense was isolated from joint fluid collected during surgery. Her condition improved after treatment with amikacin and imipenem [5].

This is the first case report of M. aubagnense isolated from ascites. Although the patient was cirrhotic, his liver functions were normal, portal vein pressure was slightly high, and no bacteria or fungi were found in ascites, and the abdominal water volume was very high. Diuretic treatment did not improve his condition, but the abdominal water volume was significantly decreased after anti-NTM treatment (similar to anti-tuberculosis treatment). Thus, the M. aubagnense infection was established as the cause of the large number of ascites. This implies that M. aubagnense in ascites was the cause of refractory ascites. The patient had recurrent attacks, which were attributed to the underlying cirrhosis. In addition, during anti-NTM treatment, patients often spontaneously stop taking drugs, which they resume after the re-emergence of symptoms. This results in a prolonged treatment cycle, which may decrease the sensitivity of pathogenic bacteria to drugs, resulting in reduced drug efficacy or ineffectiveness. In clinical cases of refractory ascites, the presence of M. aubagnense infections or missed diagnoses should be considered. In addition, there is a likelihood of the absence of clinical symptoms when abdominal cavities are only infected with M. aubagnense, with clinical symptoms only occurring when the abdominal cavity is complicated with ascites or other celiac diseases. Therefore, M. aubagnense infections should be considered in cases of recurring refractory abdominal infection-related diseases.

The low detection rate of M. aubagnense is attributed to the low sensitivity and time-consuming nature of the first-generation sequencing technology. Besides, the clinical infection spectrum of M. aubagnense overlaps with that of Mycobacterium mucogenicum, leading to misdiagnosis in some patients. Moreover, during the initial M. aubagnense infection, the clinical manifestations are not apparent as they overlap with those of underlying diseases, which easily results in missed diagnosis. Currently, many non-tuberculous Mycobacterium-causing disease strains are not specifically identified. A rapid differentiation between NTM and Mycobacterium tuberculosis complex, including the specific recognition of NTM, is critical for informing clinical treatment and patient management.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Abbreviations

NTM:

Non-tuberculosis mycobacteria

HIV:

Human immunodeficiency virus

RGM:

Rapidly growing non-tuberculous mycobacteria

M. aubagnense :

Mycobacterium aubagnense

CT:

Computed tomography

References

  1. Toïdi A, Pierre B, Didier R, et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol. 2006;56(Pt1):133–43.

    Google Scholar 

  2. Toïdi A, Michel D. Dissection of phylogenetic relationships among 19 rapidly growing Mycobacterium species by 16S rRNA, hsp65, sodA, recA and rpoB gene sequencing. Int J Syst Evol Microbiol. 2004;54(pt 6):2095–105.

    Google Scholar 

  3. Yelei Z, Aizhen P, Lin Z, Zhengwei L, Mingwu Z, Kunyang W, Xiaomeng W, Beibei W. Prevalence and drug resistance analysis of non-tuberculous mycobacteria in Zhejiang Province [J]. Prevent Med. 2021;33(1):6–10.

    Google Scholar 

  4. Deng JP, Wang B, Bai R, Xiao B, Zhang ZD, Ning Z, Li Q, Wan KL. Identification and analysis of clinical isolates of Mycobacterium in Zigong City, Sichuan Province, 2011–2018 [J]. Dis Surveill. 2019;34(04):338–43 (Chinese).

    Google Scholar 

  5. Adékambi T. Mycobacterium mucogenicum group infections: a review. Clin Microbiol Infect. 2009;15(10):911–8.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the patient for permitting us to publish this information.

Funding

This work was supported by the Guangxi Natural Science Foundation of China (2022GXNSFAA035460, 2022GXNSFBA035485). The role of funding agencies is to design research, collect, analyze and interpret data, and write papers.

Author information

Authors and Affiliations

Authors

Contributions

YD, JH, and HH designed the clinical treatment plan for the patient. RZ2 and JX performed the patient follow up duties after treatment. YN, RZ1, WS, QT, XX and JJ were involved in data collection and analysis. YD wrote the first manuscript draft. JH and HH revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jingjing Huang.

Ethics declarations

Ethics approval and consent to participate

This study was conducted in accordance with the CARE guidelines. The patient was identified during routine clinical practice and voluntarily consented to participate in the study after the details had been explained to him. Approval by the ethical committee of the First Affiliated Hospital of the Guangxi University of Chinese Medicine was waived as the study was majorly observational.

Consent for publication

The patient provided written informed consent to publish his personal data, including images and clinical details.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Du, Y., Huang, J., Nong, Y. et al. A case of ascetic fluid Mycobacterium aubagnense infection in a patient with severe peritoneal effusion. BMC Infect Dis 23, 84 (2023). https://doi.org/10.1186/s12879-023-08041-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-023-08041-1

Keywords